The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Review of bupropion for smoking cessation
Open accessAbstract
The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the options available for smoking cessation pharmacotherapy. Bupropion is a selective re‐uptake inhibitor of dopamine and noradrenalin which prevents or reduces cravings and other features of nicotine withdrawal. Bupropion is a useful oral and non‐nicotine form of pharmacotherapy for smoking cessation. For this review a total of 221 papers were reviewed plus poster presentations. This review examines in detail original clinical trials on efficacy, categorised according to whether they were acute treatment trials in healthy smokers; studies in specific populations such as people with depression, chronic obstructive pulmonary disease (COPD) or cardiovascular disease; or relapse prevention studies. Overall, these studies in varying populations comprising over four thousand subjects, showed bupropion consistently produces a positive effect on smoking cessation outcomes. The evidence highlights the major public health role that bupropion has in smoking cessation. The methodological issues of published clinical trials reporting one year outcomes were examined in detail including: completeness of follow‐up; loss to follow‐up; intention to treat analysis; blindness of assessment; and validation of smoking status. The review discusses contraindications, adverse effects, dose and overdose, addictive potential, and the role of bupropion in reducing cessation‐related weight gain. Bupropion combined with or compared to other pharmacotherapies (nicotine patch; nortriptyline) is considered. Impressive evidence exists for the use of bupropion in smoking cessation among difficult patients who are hard‐core smokers such as those with cardiovascular disease, chronic obstructive pulmonary disease (COPD) and depression. Bupropion reduces withdrawal symptoms as well as weight gain and is effective for smoking cessation for people with and without a history of depression or alcoholism. Serious side effects of bupropion use are rare. The major safety issue with bupropion is risk of seizures (estimated at approximately 0.1%) and it should not be prescribed to patients with a current seizure disorder or any history of seizures. In clinical trials of bupropion for smoking cessation no seizures were reported. Allergic reactions occur at a rate of approximately 3% and minor adverse effects are common including dry mouth and insomnia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Prevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058
Predicting Smoking Cessation: Who Will Quit With and Without the Nicotine Patch
Kenford, S. L. (1994) · JAMA · doi:10.1001/jama.271.8.589 · Cited by 405
Cohen, S., Lichtenstein, E., Prochaska, J. O., Rossi, J. S., Gritz, E. R., Carr, C. R., Orleans, C. T., Schoenbach, V. J., Biener, L., Abrams, D., et al. (1989) · American Psychologist · doi:10.1037/0003-066x.44.11.1355 · Cited by 315
Tonstad, S. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00003-4 · Cited by 246
Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation
Pierce, J. P. (2002) · JAMA · doi:10.1001/jama.288.10.1260 · Cited by 240
Dunner, D. L., Zisook, S., Billow, A. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0705 · Cited by 180
Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers
Gourlay, S. G., Forbes, A., Forbes, A., Marriner, T., Pethica, D., & McNeil, J. J. (1995) · BMJ · doi:10.1136/bmj.311.7001.363 · Cited by 104
Recycling with nicotine patches in smoking cessation
TØNNESEN, P., NØRREGAARD, J., SÄWE, U., & SIMONSEN, K. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02060.x · Cited by 48
Heavy Smokers, Smoking Cessation, and Clonidine: Results of a Double-blind, Randomized Trial
Glassman, A. H. (1988) · JAMA · doi:10.1001/jama.1988.03720190031026
Cited by
Food cue reactivity and craving predict eating and weight gain: A meta-analytic review
Boswell, R. G., & Kober, H. (2016) · Obesity Reviews · doi:10.1111/obr.12354 · Cited by 703
“Similarly, in drug addiction, such pharmacotherapies reduce craving for and consumption of alcohol (174,175), methamphetamine (176) and nicotine (177).”
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour
Laviolette, S. R., & van der Kooy, D. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1298 · Cited by 456
Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259
Tønnesen, P., Carrozzi, L., Fagerström, K. O., Gratziou, C., Jimenez-Ruiz, C., Nardini, S., Viegi, G., Lazzaro, C., Campell, I. A., Dagli, E., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00060806 · Cited by 254
Metadata
- Authors
- RICHMOND, R., & ZWAR, N.
- Venue
- Drug and Alcohol Review
- Publisher
- Wiley
- Published
- 2003-06
- Volume
- 22
- Issue
- 2
- Pages
- 203-220
- ISSN
- 0959-5236 (ISSN-L)
- 1465-3362
- OpenAlex
- W2157000531
- Cited by
- 169
- References
- 10
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of bupropion for smoking cessation. https://app.cochat.ai/papers/10.1080/09595230100100642
- The paper
- RICHMOND, R., & ZWAR, N. (2003). Review of bupropion for smoking cessation. Drug and Alcohol Review. https://doi.org/10.1080/09595230100100642
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.